Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury (NCT01223053) | Clinical Trial Compass
WithdrawnPhase 3
Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury
Stopped: Revised Development Program
0
Plain-language summary
Transdel Pharmaceuticals is investigating a topical cream formulation consisting of 10% ketoprofen for the local treatment of pain associated with mild to moderate acute soft tissue injury in this confirmatory Phase 3 trial.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Are male or female and 18 to 75 years of age, inclusive.
* Female patients of childbearing potential must practice abstinence or be using a medically acceptable form of contraception
* Have a diagnosis of uncomplicated acute soft tissue injury of the upper or lower extremity, including acute injuries of ligaments, tendons, or muscles (including Grade 1 or Grade 2 sprain or strain), that has occurred within the 60 hours preceding the baseline visit.
* Meet pain intensity criteria
* Are willing to discontinue use of any pain medication or treatments not provided as part of the study.
Exclusion Criteria:
* Participation in a previous clinical study with the drug TDLP-110 (ketoprofen 10% cream).
* Are pregnant or lactating.
* Have a Grade 3 sprain or strain, bilateral sprain or strain, or concomitant fracture or open wound at the site of the sprain or strain, or have a serious injury, as determined by the investigator
* Have a shoulder (rotator cuff) injury.
* Have been treated for a sprain or strain of the same site within the past 3 months.
* Have contusions at the site of acute soft tissue injury intended for treatment.
* Have active skin lesions or disease at the intended site of application of the study medication.
* Have had pharmacologic treatment for the injury less than 24 hours before the baseline assessments
* Use of any oral or parenteral corticosteroids within 30 days of injury.
* Have had non-pharmacologic treatments of the injury other than…
What they're measuring
1
Change from baseline in mean pain intensity (100 mm VAS) during daily activities over the past 24 hours at the Day 3 visit (Day 3 +1)